Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascentage's Cancer Drug Candidate Advances toward US/China Trials

publication date: Dec 26, 2016
China's Ascentage Pharma reported two milestones for APG-1252, a novel Bcl-2/Bcl-XL inhibitor. In the US, the FDA granted Investigational New Drug approval for APG-1252 as a small-cell lung cancer treatment, and in China, the CFDA accepted the IND filing for the candidate. APG-1252 is a small molecule drug with a programmed cell death process (apoptosis) mechanism. Ascentage said APG-1252 is its sixth program to enter clinical developments worldwide and its third program to start US clinical trials. Ascentage is headquartered in Hong Kong with an R&D lab in Shanghai and a lab-manufacturing facility in Taizhou's China Medical City. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital